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Abstract. Oestrogen receptor (ER) expression is routinely
measured in breast cancer management, but the clinical merits
of measuring progesterone receptor (PR) expression have
remained controversial. Hence the major objective here was to
assess the potential of PR as a predictor of response to
endocrine therapy. We report analyses of the relative
importance of ER and PR for predicting prognosis using robust
multilayer perceptron artificial neural networks. Receptor
determinations use immunohistochemical (IHC) methods or
radioactive ligand binding assays (LBA). In view of the
heterogeneity of intratumoral receptor distribution, we
examined the relative merits of the IHC and LBA methods. Our
analyses reveal a more significant correlation of IHC-
determined PR than ER with both nodal status and 5-year
disease-free survival (DFS). In LBA, PR displayed higher
correlation with survival and ER with nodal status. There was
concordance of correlation of PR with DFS by both IHC and
LBA. This study suggests a clear distinction between PR and
ER, with PR displaying greater correlation than ER with
disease progression and prognosis, and emphasises the marked
superiority of the IHC method over LBA. These findings may
be valuable in the management of patients with breast cancer.
Breast cancer treatment and patient management is based on
the state of progression of the disease. The assessment of
prognosis and determination of the mode of treatment has
traditionally relied on histological grade, tumour stage,
vascular and lymphatic invasion and hormone receptor status.
Various combinations of these are employed to predict
prognosis and determine risk groups. But the utility of this
approach might be limited since it cannot be employed in
determining the prognosis of individual patients. In recent
years, much effort has been made to identify molecular and
cell markers that might have the potential to assess the state
of progression and predict prognosis accurately. Molecular
subtyping of breast cancers into luminal A [oestrogen
receptor (ER) and/or progesterone receptor (PR+)/epidermal
growth factor receptor (HER2)−; low Ki67)], luminal B [ER+
and/or PR+/HER2+ (or HER2− with high Ki67)], HER2
subtype (HER2+/ER−/PR−) and basal-like (ER−/PR−/HER2−/
cytokeratin 5/6+ or EGFR+) (1) reflects tumour
aggressiveness and prognosis. It is often applied in research
since individually these parameters are known to influence
tumour growth, dissemination and progression. However, the
complexity associated with the subtyping system and the
panel of parameters involved has made extracting clinically
valuable prognostic information somewhat difficult.
Molecular subtyping implicitly embraces the relative
importance of ER and PR as prognostic markers. 
Historically, ER and PR are known to affect the growth of
a variety of tissues, including breast tissue. ER− tumours are
resistant to anti-oestrogen therapy, display rapid growth and
result in poor outcome for patients. That PR expression
might be an important prognostic marker was suggested
some years ago (2, 3). However, the measurement of PR
expression in patient management has not been accorded a
significant role and more emphasis on assessing PR status
has been advocated (4), Functional PR might be required for
proper growth signalling by ER. Patients with breast cancer
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expressing both receptors have the best prognosis and are
more likely to respond to hormone treatment than patients
with ER−/PR− tumours (5). Combining ER/PR expression
with characteristics of cell proliferation can accurately
predict nodal involvement and 5-year disease-free survival
(DFS) of patients with breast cancer (6). Patients with PR+
disease appear to respond better to hormonal therapies and
survive longer (7). Dowsett et al. found that patients with
breast cancer with low ER, PR and HER2 treated with
tamoxifen and the aromatase inhibitor anastrozole had poor
prognosis and recurrence was also inversely related to
receptor expression (8). Recently, Purdie et al. reported that
the molecular subtype luminal A reflects the best prognosis
(9). Indeed, patients with PR+ disease have not only been
known to respond to endocrine therapy but have also been
regarded to have good prognosis in terms of overall survival
(OS). The importance of PR is underscored by the
suggestion that the luminal A subtype should be redefined
on account of the consistently higher expression of PR in
that subtype as compared with luminal B (10). Several years
ago, Horwitz and McGuire described PR as an oestrogen-
responsive gene (2). But some ER−/PR+ tumours display
greater response to endocrine therapy than ER−/PR− tumours,
suggesting that PR may lead to good clinical outcome
independently of ER (5, 11). Finally, it ought to be recalled
here that three PR isoforms, namely PRA, PRB and PRC,
have been identified, which appear to have different
functions (12). The differential roles of PR isoforms was
emphasised some time ago, with high PRA expression being
correlated with tumour relapse, and breast cancer 1 (BRCA1)
and breast cancer 2 (BRCA2) mutations being associated
with high PRA expression (13, 14). Differential expression
of the isoforms has been linked with methylation of the PR
gene and is associated with outcome (15).
Since ER can induce the expression of PR, a reduced
response to hormones in patients with ER+ disease could
indicate a non-functional state of ER. In breast cancer cells,
both oestrogen and progesterone can activate the
SRC/extracellular signal – regulated kinase (SRC/ERK)
pathway and promote cell proliferation. Ballaré et al. have
attributed this to the presence of two domains of PR which
interact with ER (16). Conversely, PR has now been
recognised to be able to regulate ER function in breast
cancer (17). Progesterone was also shown to negatively
regulate other oestrogen-regulated signalling pathways,
leading to the inhibition of proliferation (18). The
importance of ER/PR is further highlighted by the possibility
that ER/PR signalling can interact with the p53 pathway.
Mouse double minute 2 homolog (MDM2) is known to
mediate the function of both p14ARF and p53. It is of interest
to note in this context that ER has been implicated in the
regulation of the p14ARF−MDM2−p53 pathway (19).
Furthermore, ER has been linked with signalling by
epidermal growth factor receptor (EGFR) and human
epidermal growth factor receptor 2 (HER2). Both EGFR and
the HER2 are said to activate ER and its co-activator
amplified in breast cancer-1 (AIB1) (20). Given that both
growth factor receptors can collaborate in generating
phenotypic effects via activation of nuclear factor kappa
B/Phosphatidylinositol-3-kinase and protein kinase B
(NFĸB/PI3K-AKT) activation, ER signalling is rightly
credited with a major role in cancer progression (21).
With this background, it seemed eminently worthwhile to
attempt to determine the relative, as well as individual,
relevance of ER and PR to breast cancer progression. The
clinical potential of PR expression in breast cancer is
controversial. Hence the major objective of this work was to
assess the potential of PR as a predictor of response to
endocrine therapy.
Receptor assessments are made on a routine basis using
immunohistochemical (IHC) techniques. However IHC is
best described as grading tumours for receptor expression.
Assays that utilise radioactive ligands (LBA) measure the
actual levels of receptor present in a tumour but, unlike IHC,
give an overall picture of expression without providing
information on the intratumoral distribution of receptors.
Intratumoral heterogeneity is not an uncommon feature and
heterogeneity in the distribution of many markers including
PR, ER, p53 and the proliferative marker Ki-67 (MIB) is
encountered in breast cancer (22), so much so that small
biopsies might provide an inaccurate picture of receptor
status. Therefore the present study set itself another objective
i.e. comparing the efficiency of IHC and radioactive assays
in prediction of progression of the disease and patient
survival.
Materials and Methods 
Clinical data and methodology. The datasets used in this study
include ER and PR determinations using IHC and LBA of breast
tumours from 110 patients, together with the state of nodal
involvement and 5-year survival data. ER and PR status was
determined by conventional methods of IHC and LBA assays (23).
The full datasets analysed here are given in Tables I and II.
Methods of analysis. Initial stages of the study looked to determine
a close approximation of a patient’s survival period given the data
provided, thus the Multi-Layer Perceptron (MLP ) approach was
considered. The MLP is an artificial neural network model that
behaves through a feedforward mechanism providing a set of
outputs based on the given input data (24). This is the computational
model used in previous research which aimed for the prediction of
a specific output upon provision of certain parameters as input data.
This was the model of choice in this study, since it has been used in
several clinical studies to predict risk of mortality of stroke patients
and risk of haemorrhage in ischaemic stroke (25, 26) and for
diagnosing cardiovascular diseases (27, 28). Essentially, the model
involves assigning individual cases to a specified number of classes
and determining how many were correctly or incorrectly classified.
ANTICANCER RESEARCH 36: xxx-xxx (2016)
2
In other words, using the MLP technique, predictions are made of
the outcome, here in terms of nodal involvement and 5-year DFS,
where the correlation coefficients reflect the accuracy of
classification. Rank tests are not applied to verify the statistical
significance of the observation since there is a general perception
that unlike MLPs, they do not adequately meet the requirements for
performing multiple comparisons.
The analytical work was conducted using the University of
Waikato’s WEKA Machine Learning Tool (29). As the sample size
was small for the MLP to generate an actual prediction, the next
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Table I. Oestrogen receptor (ER) and progesterone receptor (PR) levels
in breast cancer as assayed by immunohistochemistry.
Patient ER PR Nodal status, % Date of  
ID (+fraction) (+fraction) (positive follow-up:
nodes/total Surgery to 
nodes tested) last seen
196 0.8 0.7 11.1 (3/27) 1997-2003 
199 0 0 6.7 (1/15) 1997-2003 
200 0.8 0.1 0 (0/14) 1998-2003 
201 0 0 0 (0/4) 1999-2003 
203 0.4 0.25 25 (4/16) 1999-2003 
204 0.9 0 0 (0/26) 1999-2004 
205 0 0.2 0 (0/19) 2000-2003 
206 0.22 0 7.7 (1/13) 1998-2004 
209 0.46 0.08 5.5 (1/18) 1998-2000 
213 0 0 0 (0/27) 1999-2003 
214 0.1 0.2 12.5 (3/24) 1997-2005 
219 0.95 0.16 0 (0/18) 1999-2004 
222 0.7 0.2 5 (1/20) 1996-2003 
225 0.1 0.4 7.7 (1/13) 1999-2004 
226 0.75 0 0 (0/20) 1999-2003 
227 0.9 0.33 6.2 (1/16) 1999-2003 
238 0.9 0.32 0 (0/22) 1999-2000 
231 0 0 0 (0/20) 1998-2003 
233 0.9 0.9 0 (0/11) 1997-1998 
257 0.5 0 0 (0/16) 1999-2004 
280 0 0.9 0 (0/9) 1999-2003 
294 0.8 0.15 62.5 (10/16) 1994-2001 
297 0.5 0.3 0 (0/25) 1994-2003 
309 0.9 0.1 30 (3/10) 1999-2003 
238 0 0 0 (0/12) 2003-2004 
240 1.0 1.0 0 (0/20) 2001-2004 
241 0.05 0.05 9 (1/11) 2001-2003 
243 0.9 0.8 0 (0/3) 2001-2003 
245 0 0 0 (0/25) 2002-2004 
246 0 0 0 (0/13) 2002-2004 
249 1.0 0 4 (1/25) 2004-2004 
250 0.6 0 63.6 (14/22) 2002-2004 
252 0 0 0 (0/16) 2001-2004 
254 0.8 0.49 0 (0/18) 2002-2004 
255 0 0.1 0 (0/19) 2003-2003 
258 0.8 0.6 0 (0/18) 2003-2004 
259 0.6 0.05 0 (0/16) 2002-2003 
260 0.9 0.8 31 (5/16) 2002-2003 
261 0.8 0.8 0 (0/19) 2001-2003 
262 0.9 0.7 0 (0/14) 2001-2004 
263 0.9 0.1 14 (2/14) 2004-2004 
264 0.8 0.8 33 (4/12) 2001-2004 
283 0 0 96 (24/25) 2002-2003 
267 0.7 0.9 10 (1/10) 2003-2004 
288 0.9 0.9 0 (0/11) 2000-??
311 0 0 43.7 (7/16) 2003-2004 
312 0.95 0.95 0 (0/21) 2003-2003 
313 0.9 0.4 0 (0/20) 2003-2004 
314 0.7 0.7 11 (2/18) 2003-2004 
315 0.05 0.05 0 (0/7) 2001-2004 
316 0.95 0.95 10 (2/20) 2001-2004 
317 0.9 0.7 0 (0/29) 2004-??
318 0 0 3.5 (1/28) 2003-2004 
319 0.7 0.95 0 (0/14) 2002-??
Table II. Oestrogen receptor (ER) and progesterone receptor (PR) levels
in breast cancer measured by ligand-binding assay*.
Patient ER PR Nodal status, % Date of 
ID (fmol) (fmol) (positive follow-up: 
nodes/total) Surgery to 
nodes tested last seen
183 38 140 0 (0/18) 1996-2003 
197 80-500 2 7.1 (1/14) 1997-2003 
215 80-484 90-500 0 (0/25) 1997-2001 
216 34-60 65 0 (0/12) 1996-2000 
218 64 42 100 (14/14) 1996-2000 
229 22 11 100 (20/20) 1996-1999 
230 55-80 72 5.3 (1/19) 1999-2003 
232 34-90 90-500 0 (0/12) 1999-2003 
234 90-500 10-130 10 (1/10) 1996-2004 
235 3.8 1.1 0 (0/17) 1996-2000 
236 0-2.8 0-2.2 5.5 (1/18) 1997-2000 
266 3 80 0 (0/12) 1992-2004 
267 14 50 21.4 (3/14) 1992-2003 
268 5 2 0 (0/15) 1992-2003 
269 27 6 0 (0/15) 1992-1999 
270 122 63 11 (1/9) 1992-2003 
271 1 0 5.5 (1/18) 1992-2003 
272 1 4 0 (0/22) 1992-2001 
274 1-4 5-1 16.6 (2/12) 1994-1997 
275 0-1 0-2 0 1994-2004 
276 58 388 20 (3/15) 1994-2003 
277 15-17 10-16 60 (9/15) 1994-2004 
278 2 8 0 (0/15) 1994-2002 
279 0-50 0 5.5 (1/18) 1993-1999 
281 212 43-250 0 (0/13) 1993-1997 
282 35-50 70-1077 28.5 (4/14) 1993-1996 
292 158 24 0 (0/19) 1993-2003 
293 161 160 33.3 (4/12) 1993-1998 
295 90-755 95-167 14.3 (3/21) 1993-2003 
296 18 5 27.3 (6/22) 1992-2003 
298 22 34 0 (0/17) 1992-2002 
299 93 207 0 (0/32) 1994-2001 
300 5 9 0 (0/23) 1993-2002 
301 183 8 0 (0/21) 1993-2000 
302 15-20 13 0 (0/13) 1993-2003 
305 1 4 10 (2/20) 1992-1995 
306 222 84 4.5 (1/22) 1993-??
307 550 415 0 (0/16) 1994-2004 
*Note: Where a range of values is shown, the lower value was used in
the analysis.
step was designed to determine the possibility of classifying
whether a patient would be able to survive longer than the 5-year
relative survival rate, as indicated by the National Cancer Institute’s
Surveillance, Epidemiology, and End Results Program database
(30). Adding a new label that is nominal in value produced
preliminary results (as discussed in the next section) that involved
an output of determining whether a patient’s prognosis would be a
survival period longer than 5 years, which required ER, PR, and
nodal status as input parameters. Despite the preliminary results,
further analysis of the dataset involved a large bias towards longer
survival, thus there was a need to experiment with other methods.
The next phase of experimentation focused on determining
whether PR or ER better correlated with disease progression. The
linear association between the continuous values (31) of ER or PR
and the patient’s prognosis was assessed here. This approach was
used on both IHC and LBA datasets to determine whether ER or PR
correlated with the patient’s prognosis.
Due to the results from the previous phase, further analyses were
performed where the ratio of ER to PR was analysed to determine if
a relative expression factor presented as a ratio significantly
influenced the prediction of prognosis. As the previous phase
displayed a low correlation factor, further examination showed that
the computation was affected by the varying prognosis of two
patients who had the same given values in the ER and PR field. An
example of such scenario is patient 231 compared to patient 238
from the IHC dataset indicated in Table I, where both patients had
the value of 0 provided for both ER and PR, but the prognosis was
5 years for patient 231 and only 1 year for patient 238. To address
this issue, entries of the datasets were grouped into random
subgroups within the dataset. Each subgroup was generated
randomly and with a threshold of at least 60% of the dataset
included in the subgroup, where there were no duplicate entries in
any subgroup produced. Subsequently, the correlation approach was
applied to each subgroup.
The aforementioned approach was applied to both the IHC and
LBA datasets, and each produced a possible moderate and high
positive correlation (32) as discussed in the next section.
Results 
Our analyses undertaken through the MLP approach suggest
that IHC-determined PR expression shows greater correlation
than ER with both nodal status and 5-year DFS. But in the
LBA measurements, PR displayed higher correlation with
survival and ER with nodal status (Table III). The correlation
values were not sufficiently robust and weighty; it is
nonetheless of interest to note the apparent concordance of
correlation of PR with DFS by both IHC and LBA. These
conclusions are subject to the caveat that performance rating
of IHC and LBA from the same dataset would have been
more robust and persuasive. Furthermore, the discriminatory
effects, as indicated by the correlation coefficients resulting
from the MLP approach, are limited in this study due to the
small sample size and the biased values for prognosis which
are more heavily skewed towards surviving longer than the
5-year life expectancy.
Further analysis of the datasets indicated a possible
correlation between the ratio of ER to PR and the
prognosis of a patient’s outcome. The results presented in
Table IV were obtained by grouping users in the dataset
who survived more than the average number of years.
Regarding the patients who survived more than the average
number of years in the IHC dataset, a correlation
coefficient of 0.66 for ER/PR ratio in relation to prognosis
was found. This approach was also applied to the LBA
dataset and produced a highly significant correlation
coefficient of 0.77.
While the reference or orientation is small, the positive
correlation of the ER/PR ratio with patient prognosis was
present in both the IHC and LBA datasets, indicating the
possibility of this being a better indicator for prognosis.
ANTICANCER RESEARCH 36: xxx-xxx (2016)
4
Table III. Correlation coefficients of oestrogen receptor (ER) and progesterone receptor (PR) with nodal spread and disease-free survival (DFS) –
a comparison between immunohistochemistry (IHC) and ligand-binding assay (LBA)
IHC LBA
Parameter Nodal spread p-Value DFS p-Value Nodal spread p-Value DFS p-Value
ER −0.034 0.81 −0.081 0.571 −0.086 0.614 0.151 0.371
PR −0.119 0.403 −0.195 0.171 −0.048 0.778 0.154 0.362
Table IV. Results obtained in relation to oestrogen receptor (ER) and progesterone receptor (PR) ratio.
Parameter tested IHC LBA
Average years of survival 3.05 7.15
Proportion surviving longer than average 69.23% 64.71%
Coefficient of correlation with prognosis 0.66 (p=0.054) 0.77 (p=0.005)
These findings should be further corroborated through the
analysis of a larger dataset.
Discussion
The rationale of the analyses. This investigation focused on
three areas relevant to the role of steroid receptor
determination in the management of patients with breast
cancer. The first was to determine whether measurement of
PR in breast cancer tissues makes a significant contribution
to the prediction of the ability of breast cancer to spread to
regional lymph nodes and to the prediction of 5-year DFS of
patients. Given the emphasis on nodal involvement, we
addressed the early events of secondary spread and not the
late recurrences attributable to the presence of micro-
metastases at the onset of disease. Consistent with this is the
recent finding that low PR expression together with the
presence of Ki67 in primary tumour as well as metastases is
predictive of the pace of progression of breast cancer (33).
Considered co-operatively, the ER+/PR+ and ER+/PR−
phenotypes do not seem to differ much from the ER−/PR−
phenotype in terms of pathological features and prognosis
(34). Indeed, it has been suggested that the benefits to
patients of anti-oestrogen therapy might be superior when PR
is expressed alone than when co-expressed with ER (35).
The second point of focus was the relative importance of ER
and PR expression, individually, and in tandem with clinical
outcome. Finally, with practical implications in mind, a
comparison of the efficacy of the two methods used in the
measurement of the receptors, namely IHC and LBA assays,
to predict clinical outcome, was carried out. 
PR status correlates with nodal spread and DFS. In the
present study, far superior correlation of PR with both nodal
status and DFS was noted. In contrast, ER determined by
LBA correlated only with nodal status. This is intriguing
given that LBA determines the overall receptor content
irrespective of intratumoral distribution, which could be a
major determinant of tumour behaviour. Overall, the present
work clearly underscores earlier findings that PR has an
important contribution to make in determining the course of
patient management. 
Comparison of IHC and LBA in relation to clinical outcome.
The IHC assay is used to determine the proportion of cells
that stain positively with the respective antibodies and
tumours which are graded positive or negative using arbitrary
cut-off levels of positivity. However, the choice of cut-off
values is not standardised; hence in the present study, the
percentage of positive cells in each tumour was employed for
the analyses. 
Notwithstanding the problems associated with the absence
of standardisation, IHC assay has been regarded as more
appropriate than the LBA. It has been argued that ER
assessment by IHC is superior to LBA in that the former is
easier and less expensive and indeed might be more efficient
for predicting response to adjuvant endocrine therapy (36).
Moreover, claims have been made that IHC provides more
useful information relating to the correlation of PR and ER
with clinical outcome than that obtained using LBA (37, 38). 
However, a high degree of concordance of positivity has
been observed for both ER and PR determined by the two
methods (39, 40). 
Our analyses revealed a more significant correlation of
IHC-determined PR than ER with both nodal status and 5-
year DFS. In LBA, PR displayed higher correlation with
survival and ER with nodal status, and these findings might
be helpful at the clinical level.
Conclusion
The issues of the development of resistance or determination
of sensitivity to endocrine therapy are highly relevant in the
context of therapeutic strategy. The evaluation of the relative
potential of conventional markers is essential in order to
develop new molecular approaches to breast cancer
management. This study draws a clear distinction between
PR and ER, with PR displaying greater correlation than ER
with regard to their relationship with disease progression and
prognosis, and emphasises the marked superiority of the IHC
method over LBA. These findings may be valuable in the
management of patients with breast cancer.
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